 TORONTO, ON ACCESSWIRE August 13, 2021 Edesa Biotech, Inc. NASDAQ:EDSA, a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three and nine months ended June 30, 2021 and provided an update on its business. During the quarter, the company achieved key interim milestones for both of its lead product candidates, EB05 and EB01. 